Avosentan
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00120328)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Endothelin receptor ET-AANTAGONIST
EDNRA antagonist
Ph 3 trial Discontinueddue to adverse effects.
- Endothelin receptor ET-AINHIBITOR
EDNRA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccncc2)nc1OC- Mol. weight
- 479.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989834 ↗
- ChEMBLCHEMBL2107803 ↗
Also known as
- 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide
- avosentan
- avosentan
- avosentan
- ro 67-0565
- ro 67-0565
- ro-670565
- ro-670565
- spp301
- spp301
- spp301
- spp-301
- spp-301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00120328 | Phase 3 | Jul 1, 2005 | Speedel Pharma Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Speedel Pharma Ltd. | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1